Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Diagnosis
74 results:
1. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
2. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic capability of 18F-PSMA PET-MRI and pelvic MRI plus bone scan in treatment-naive prostate cancer: a single-center paired validating confirmatory study.
Qiao Z; Wang S; Wang H; He B; Shi Z; Zhou H; Yang Q; Chen X; You Z; Zhao J; Wang H
Int J Surg; 2024 Jan; 110(1):87-94. PubMed ID: 37738021
[TBL] [Abstract] [Full Text] [Related]
4. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive prostate cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
6. Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With prostate cancer.
Chávarri-Guerra Y; Bourlon MT; Rodríguez-Olivares JL; Orozco L; Bazua D; Rodríguez-Faure A; Alcalde-Castro MJ; Castro E; Castillo D; Herzog J; Weitzel J
Clin Genitourin Cancer; 2023 Oct; 21(5):569-573. PubMed ID: 37380563
[TBL] [Abstract] [Full Text] [Related]
7. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
8. Educational differences in healthcare use among survivors after breast, prostate, lung, and colon cancer - a SEQUEL cohort study.
Levinsen AKG; Kjaer TK; Maltesen T; Jakobsen E; Gögenur I; Borre M; Christiansen P; Zachariae R; Laurberg S; Christensen P; Kroman N; Larsen SB; Degett TH; Hölmich LR; Brown PN; Johansen C; Kjær SK; Thygesen LC; Dalton SO
BMC Health Serv Res; 2023 Jun; 23(1):674. PubMed ID: 37349718
[TBL] [Abstract] [Full Text] [Related]
9. Recurrent germline variant in atm associated with familial myeloproliferative neoplasms.
Braunstein EM; Imada E; Pasca S; Wang S; Chen H; Alba C; Hupalo DN; Wilkerson M; Dalgard CL; Ghannam J; Liu Y; Marchionni L; Moliterno A; Hourigan CS; Gondek LP
Leukemia; 2023 Mar; 37(3):627-635. PubMed ID: 36543879
[TBL] [Abstract] [Full Text] [Related]
10. Prior Thyroid and Nonthyroid cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid cancer.
Chen YH; Cabanillas M; Sperling J; Xu L; Goswami M; Maniakas A; Williams MD; Lai SY; Busaidy N; Dadu R; Zafereo ME; Wang JR
Thyroid; 2023 Mar; 33(3):321-329. PubMed ID: 36511380
[No Abstract] [Full Text] [Related]
11. Germline Variants in DNA Damage Repair Genes and
Trendowski MR; Sample C; Baird T; Sadeghpour A; Moon D; Ruterbusch JJ; Beebe-Dimmer JL; Cooney KA
JCO Precis Oncol; 2022 Nov; 6():e2200460. PubMed ID: 36446039
[TBL] [Abstract] [Full Text] [Related]
12. Characteristics of BRCA2 Mutated prostate cancer at Presentation.
Han H; Park CK; Cho NH; Lee J; Jang WS; Ham WS; Choi YD; Cho KS
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362213
[TBL] [Abstract] [Full Text] [Related]
13. Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men.
Huang J; Zhao B; Weinstein SJ; Albanes D; Mondul AM
BMC Med; 2022 Oct; 20(1):362. PubMed ID: 36280842
[TBL] [Abstract] [Full Text] [Related]
14. B7-H3 as a Therapeutic Target in Advanced prostate cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract] [Full Text] [Related]
15. Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.
van Winden LJ; Lentjes EGWM; Demir AY; Huijgen HJ; Bergman AM; van der Poel HG; van Rossum HH
Clin Chem Lab Med; 2022 Sep; 60(10):1661-1668. PubMed ID: 35918785
[TBL] [Abstract] [Full Text] [Related]
16. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive prostate cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract] [Full Text] [Related]
17. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: atm, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract] [Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
19. Association of Blood Pressure with prostate cancer Risk by Disease Severity and prostate cancer Death: A Pooled Cohort Study.
Jochems SHJ; Häggström C; Stattin P; Järvholm B; Stocks T
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1483-1491. PubMed ID: 35511742
[TBL] [Abstract] [Full Text] [Related]
20. Hereditary cancer Gene Variants in Hispanic Men With a Personal or Family History of prostate cancer.
Ramamurthy C; Stutz EW; Goros M; Gelfond J; Johnson-Pais TL; Thompson IM; Leach RJ; Liss MA
Clin Genitourin Cancer; 2022 Jun; 20(3):237-243. PubMed ID: 35260348
[TBL] [Abstract] [Full Text] [Related]
[Next]
